4 results about "Mycoplasmata" patented technology

This application discloses a Mycoplasma pneumoniae P1 protein-binding protein, its preparation method, and its uses. The Mycoplasma pneumoniae P1 protein-binding protein includes an immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1-8. The bivalent or multivalent nanobodies prepared using this Mycoplasma pneumoniae P1 protein-binding protein can effectively enhance their binding strength to antigens, providing a superior raw material for developing highly sensitive detection and diagnostic applications.

This invention relates to a novel fusion protein, immunogenic composition, recombinant vaccine, molecular architecture design, and applications for the prevention and treatment of Mycoplasma pneumoniae infection. The invention provides a novel fusion molecular architecture comprising fusion proteins encoded by the PstS and P37 genes, which can be used in the development of nucleic acid vaccines. The invention reveals that the novel fusion protein exhibits excellent immunogenicity, providing effective immune protection, significantly inhibiting Mycoplasma pneumoniae colonization, and, compared to nucleic acid vaccines encoding the P1-P30 fusion protein, which are known in the art to have excellent efficacy, demonstrates a more significant immune effect and protective effect against Mycoplasma pneumoniae infection, showing broad application prospects.

This invention discloses a triple inactivated vaccine against porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae, and Streptococcus suis, and its preparation method, belonging to the field of veterinary biological products technology. The invention consists of an antigen and a vaccine adjuvant; the antigen is composed of PCV2 antigen, Mycoplasma hyopneumoniae antigen, and Streptococcus suis antigen; the PCV2 antigen is the PCV-2 d-cap protein obtained through genetic engineering; the Mycoplasma hyopneumoniae antigen is inactivated Mycoplasma hyopneumoniae (ES-2) bacterial suspension; the Streptococcus suis is inactivated SS2 and SS9 type Streptococcus suis bacterial suspension; the adjuvant is a novel aqueous adjuvant capable of enhancing cellular and humoral immunity. The triple inactivated vaccine against PCV2, Mycoplasma hyopneumoniae, and Streptococcus suis provided by this invention exhibits significant advantages in preventing these three swine diseases.

The application belongs to the technical field of nucleic acid aptamer, and provides an application of an aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein. The aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein is labeled with a fluorescent marker on a base sequence shown in SEQ.ID.NO.1. The nucleic acid aptamer obtained by the application has high specificity and high affinity for mycoplasma pneumoniae P1 adhesion protein, the Kd value is 392.8 nM, the linear detection range is 480-1200 nM, and the detection limit is 145.50 nM. The application can be used for visual detection of mycoplasma pneumoniae P1 adhesion protein, and has a good application prospect.